The future of obesity: a conversation with Mads Thomsen

For more than two decades, Mads Thomsen was the driving force behind Novo Nordisk’s pipeline, from building its dominant position in diabetes to its first-mover push into obesity with the success of its GLP-1 semaglutide franchise.

Rapidly rising revenues from Type II diabetes treatments Ozempic semaglutide, Rybelsus semaglutide and obesity therapy Wegovy semaglutide — all of which Thomsen shepherded through discovery, development and onto the market — have sparked an explosion of interest from investors and positioned obesity as the next megablockbuster indication. ...